尽管在做放疗和化疗，古蒂于2月份就知道癌细胞已经转移到其它器官，而且被告知生存的时间只有很短了。
Despite undergoing radiotherapy and chemotherapy, Goody learned in February that cancer had spread to other organs and was warned she had only a short time to live.
二级终点包含了目标反应率，一年生存期，总生存率，化疗类型和安全性PFS评估。
Secondary endpoints included objective response rate, one-year survival rate, overall survival, PFS assessment by chemotherapy type and safety.
前两期研究表明胰腺癌患者接受较大剂量放疗和化疗有助增加生存期。
Two other studies suggest that giving patents with pancreatic cancer more intense radiation and chemotherapy could extend survival.
对晚期的乳腺癌患者，经过化疗和内分泌治疗后，5年生存率仍可达到25%以上。
To the later period breast cancer patient, after passing through the chemotherapy and the endocrine treatment, 5 year survival rate still might achieve above 25%.
放疗和基于顺铂的化疗联合治疗可以改善宫颈癌患者的生存率。
Survival rates for women with cervical cancer improve when radiotherapy is combined with cisplatin-based chemotherapy.
接下来，医生就能使用放疗和化疗结合的方法来治疗肿瘤，以延长非小细胞型肺癌患者的生存率。
This allowed the doctors to then focus on treating the tumor site in the lungs with a combination of radiation and chemotherapy, helping to extend the survival rates of patients with NSCLC.
结论癌肿姑息切除联合肝动脉置管埋泵化疗有助于提高中晚期肝癌患者的生存时间和生命质量。
Conclusions Palliative resection of liver cancer and implanted with a drug delivery system can improve survival duration and life quality of patients with advanced HCC.
目的：探讨胃癌术后腹腔温热灌洗化疗对胃癌术后腹膜转移和生存率的影响。
Objective: to analyze the effect of intraperitoneal hyperthermic perfusion chemotherapy on the postoperative metastatic rate and survival rate.
结论早期诊断、手术切除加术后联合化疗是提高胃原发性恶性淋巴瘤生存率和改善预后的关键。
Conclusion: Early diagnosis, Resection and postoperative chemotherapy are the key facts to improve survival rate of patients with primary gastric malignant lymphoma and improving prognosis.
观察两组患者的临床疗效、组织学疗效、对化疗的毒副反应，以及术后3年生存率和无病存活率，并进行对比分析。
The clinical and histological effects, toxic and side reaction of chemotherapy such as nausea and vomit, the 3-year survival rates and disease-free survival rates were analyzed.
结论放化疗综合治疗N2、N3期鼻咽癌有助于提高短、中期生存率，减少局部复发和远处转移。
Conclusion Radiotherapy with chemotherapy can increase the survival rates and decrease the distant metasis in patients with N2, N3 stage nasopharyngeal carcinoma.
【译】KRAS基因密码子12和13与无病生存的野生型BRAF的II I期结肠癌辅助化疗试验从一个突变(n0147联盟)。
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance).
目的观察剂量密度化疗治疗乳腺癌的不良反应及对无病生存期和总生存期的影响。
Objective to investigate the adverse effect, disease free survival and overall survival of dose-dense chemotherapy in postoperative breast cancer patients.
目的比较食管癌放射治疗加化疗与单纯放射治疗的近期疗效和生存率。
Objective To compare the survival rate and short-term results between radiotherapy combined with chemotherapy and radiotherapy alone in treatment of esophageal cancer.
结论腹腔热灌注化疗能明显提高胃癌术后病人的生存率和生存质量。
Conclusion IPHP with chemotherapeutic agents can improve the survival rate and life quality of postoperative stomach cancer patients.
医生发现，与只接受同步放化疗的患者相比，接受诱导治疗和同步放化疗的患者，其总生存率升高较小，但很显著。
Doctors found a small but significant increase in overall survival in the patients who received the induction therapy with chemoradiation versus the chemoradiation-only group.
对于OSCST,FIGO分期、规范化疗分别是影响生存率和复发与未控率的因素。
FIGO stage and standard chemotherapy were favourable factors for prognosis in OSCST group.
观察经验方养胃合剂对接受放化疗的癌症患者免疫功能和生存质量方面的影响。
Objective :The trial is to observe the effect of "YANGWEIHEJI" acting on immunity and quality of life of tumor patients.
同期收治2例广泛期行单纯化疗，生存时间分别为2个月和7个月。
In the same time, two extended stage patients treated with chemotherapy only and died within 2 month and 7 month respectively.
方法随机分为腹腔化疗组35例和静脉化疗组21例，记录观察近期疗效和毒副反应，随访患者并计算生存期。
Methods the patients were randomly divided into two groups: 35 cases in the intraperitoneally treated group and 21 cases in the intravenously treated group.
目的探讨肝癌合并门静脉癌栓的手术疗效，评价术中门静脉癌栓取出术和术后辅助肝动脉栓塞化疗对提高肝癌术后生存率的影响。
Objective To explore the value of removing portal vein tumor thrombus (PVTT) and TACE in improving the outcome of resection for primary liver cancer with PVTT.
结论选择性肺动脉灌注化疗用于肺叶切除术后的肺癌患者，能够杀灭和抑制局部微转移灶，减少局部复发和远期血行转移的发生率，提高长期生存率。
Conclusion Pulmonary artery infusion for lung cancer patients after lobectomy can reduce the post operative recurrence and metastasis and improve the long term survival rates.
结果扩大根治切除、新辅助放疗化疗、原位肝移植、光动力学治疗和分子放化疗均能有效地提高患者的生存率。
Results Extended radical resection, neoadjuvant chemotherapy, orthotopic liver transplantation, photodynamic therapy and molecular chemoradiotherapy might improve the survival rate.
目的比较肝动脉化疗栓塞(a组)和肝脾动脉双栓塞(B组)治疗肝癌并肝硬化病人的反应率、生存率、并发症和毒副作用。
Objective to compare the effects of transcatheter hepatic arterial chemoembolization (a arm) with hepatic and splenic arterial double embolization (b arm) on hepatoma complicated with cirrhosis.
结论短疗程、高强度化疗结合中枢神经系统预防的治疗策略能明显改善儿童青少年B - NHL患者的疗效和生存率，特别是对晚期患者的疗效更明显。
Conclusion Short term and intensive chemotherapy can improves the efficacy and survival rate of childhood and adolescent B-NHL, especially for advanced stage patients.
另外，对5例化疗患者和10例非化疗患者(均为高危组MDS患者)进行中位生存期和生存率比较。
Besides, compare median survival time with survival rate for 5 cases of chemotherapy group and 10 cases of non-chemotherapy group (the high-risk group of MDS patients). Results: 1.
结论：DCIK联合化疗治疗晚期肺癌具有更好的疗效，其生活质量、免疫功能和生存率有一定的提高。
Conclusion: DCIK combined with chemotherapy shows a better clinical efficacy in treatment of advanced lung cancer, with improved quality of life, immune function and survival rate.
随着骨肉瘤治疗手段的进展，如扩大切除术、放疗和新辅助化疗，其5年生存率已经增加到50～60%。
With current therapies of OS, such as extensive surgical excision, radiotherapy and neoadjuvant chemotherapy, five-year survival rate has increased up to 50%-60%.
手术后合并化疗的综合治疗组和单纯手术治疗组的5年生存率差异有统计学意义（P＜0.05）。
The differences of 5-year survival rate between the post-operative comprehensive treatment group and only operation group had statistical significance (P<0.05).
手术后合并化疗的综合治疗组和单纯手术治疗组的5年生存率差异有统计学意义（P＜0.05）。
The differences of 5-year survival rate between the post-operative comprehensive treatment group and only operation group had statistical significance (P<0.05).
应用推荐